JAAD 06/23 Immunotherapy for Keratinocyte Cancers. Part 2: Identification and Management of Cutaneous Side Effects of Immunotherapy Treatments

JAAD 01/23 Dysplastic Nevus Part I: Historical Perspective, Classification, and Epidemiology

JAAD 03/23 Risk of melanoma and nonmelanoma skin cancer with immunosuppressants. Part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids

JAAD 01/23 Dysplastic Nevus Part II: Dysplastic Nevi: Molecular/Genetic Profiles and Management

JAAD 02/23 Disorders of Hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders

JAAD 05/23 An Update on Viral Induced Cutaneous Lymphoproliferative Disorders. A Review from the Ibero-American Society of Dermatopathology (SILADEPA). CME Part I.

JAAD 05/23 An Update on EBV and HTLV-1 Induced Cutaneous Manifestations. A Review of the Ibero-American Society of Dermatopathology

JAAD 02/23 Disorders of Hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation

JAAD 04/23 Skin disorders and interstitial lung disease. Part I. Screening, Diagnosis and Therapeutic Principles

JAAD 03/23 Risk of melanoma and nonmelanoma skin cancer with immunosuppressants. Part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors